AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 171 min read$AEMD

Biotech Pre-Market Movers: AEMD, VEEA Surge; LGVN, ALMU Slide

Aethlon Medical (AEMD) surged over 400% after announcing a merger with North Immunology. BioAffinity Technologies (VEEA) also rose following a Hong Kong patent grant for its CyPath Lung diagnostic. Other biotech stocks saw mixed pre-market activity.

Original reporting
rttnews.com
Published Sep 17, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 2:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$AEMD
Bullish
high confidence
Mentioned
$AEMD
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$AEMDBullishHigh
01

Why it matters

Aethlon Medical's merger announcement is the primary catalyst for its surge; other names are peripheral.

02

Market read

Merger news creates immediate trading opportunity in AEMD; broader biotech sentiment may shift.

03

What to watch

Deal financing and regulatory approval could delay or derail the transaction.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Pre‑market movers list highlights biotech stocks reacting to recent news.

Company-level read

Ticker impact

$AEMDBullishHigh confidence
Context

Aethlon Medical announced a merger with North Immunology, driving a >400% pre‑market surge.

Expected impact

Expect continued upside as deal details are clarified; watch for volatility.

Evidence & confidence

First‑report merger announcement for a listed micro‑cap; price already reacted dramatically.

Market effects

Sector

Biotech sector may see heightened interest in M&A activity.

Regional

U.S. biotech pre‑market activity lifts related stocks.

Global

Limited to U.S. biotech investors.

Counterpoint

What could challenge this read

Rapid price rise may be speculative; consider downside risk if merger terms are unfavorable.

Key entities

  • Company
    Aethlon Medical

    Biotech firm merging with North Immunology.

  • Company
    North Immunology

    Merger partner of Aethlon Medical.

Read at source← All news

Related articles

SEP 21
$LSTAHighAI 9/10

Lisata and Aethlon close reverse merger deals

Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock deal with a $225M private placement, gaining access to Marea's cardioendocrine pipeline. Aethlon Medical merged with North Immunology in an all-stock deal with a $180M private placement, focusing on NOR-101 for atopic dermatitis. Both deals aim to advance pipelines and create value for shareholders.

bioxconomy.com2 min
SEP 18
$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

rttnews.com3 min
SEP 17
$AEMDHighAI 9/10

Medical Tech Stock Aethlon Medical, Inc. (Nasdaq: AEMD) Soars on Merger News

Aethlon Medical (AEMD) stock surged 393% after announcing a merger with North Immunology, a biotech developing treatments for immune and inflammatory diseases. The all-stock deal includes a $180M private placement and aims to advance NOR-101, a bispecific antibody for atopic dermatitis. The combined company will trade on Nasdaq under NRTX, with Aethlon shareholders owning 4.75% post-merger.

investorideas.com2 min